PDCD1 and colorectal carcinoma: In preclinical models of MSS-type CRC, such approaches demonstrate dual therapeutic benefits: alleviating the immune-cold TIME and synergizing with anti-PD-1 therapy to enhance treatment efficacy [60] (Figure 3).